A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer

This study is a multicenter randomized controlled clinical trial targeting subjects with advanced or metastatic squamous NSCLC with unknown or negative gene status, aiming to evaluate the efficacy and safety of first-line delayed administration of Serplulimab combined with a low-dose Nab-Paclitaxel doublet chemotherapy regimen.

Trial Details

NCT ID

NCT07647094

Phase

PHASE2

Sponsor

People's Hospital of Quzhou

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Serplulimab, Nab-Paclitaxel, Carboplatin

Locations (sample)

Quzhou, Zhejiang, China|28.95944,118.86861

Key Eligibility Criteria

Sign a written informed consent before implementing any trial-related procedures;
Age ≥18 years and ≤75 years;
Histologically or cytologically confirmed locally advanced (IIIB-IIIC), metastatic, or recurrent (stage IV) squamous NSCLC (according to the 8th ed…
Unknown gene status, or known histological specimen gene status confirming no EGFR gene-sensitive mutations or ALK gene fusion variations;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →